title: StemCells, Inc.: Clinical trials of stem cell therapies for CNS disorders. Interview with Martin McGlynn.
abstract: Martin McGlynn, President & Chief Executive Officer of StemCells, Inc., talks to Regenerative Medicine about the company's ongoing clinical trials with their human neural stem cell treatment (HuCNS-SC). Martin McGlynn joined StemCells, Inc. in January of 2001 as President and Chief Executive Officer, and was elected to its Board of Directors on February 6, 2001. Martin McGlynn has spent several decades as a senior executive in the life sciences industry in Europe, Canada and the USA. He began his career in Manufacturing Operations with Becton Dickinson, Ireland Ltd. then joined Abbott Labs in 1977 where he held positions as General Manager, Abbott Ireland Ltd, President and General Manager of Abbott Canada Ltd and Vice President of Abbott International Ltd. Martin McGlynn currently serves as a member of the Board of the Alliance for Regenerative Medicine and is co-Chairman of its Operations and Governance Committee.
authors.forename: Martin
authors.initials: M
authors.lastname: McGlynn
mesh_terms: D000328:Adult; D053687:Adult Stem Cells / Q000166:cytology; D002493:Central Nervous System Diseases / Q000473:pathology / Q000628:therapy*; D002648:Child; D002986:Clinical Trials as Topic; D004345:Drug Industry; D006801:Humans; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000166:cytology*; D014184:Transplantation, Homologous